Periodontopathogens antibodies and major adverse events following an acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI).
BACKGROUND
Periodontopathogens antibodies have been shown to be associated with primary myocardial events, but little is known regarding their impact on major adverse events after a prior acute myocardial infarction (AMI). The present prospective study evaluates the association between antibody levels of 4 periodontopathogens and the risk of all-cause death or non-fatal myocardial infarction (MI) at 1 year in 975 patients admitted for acute ST segment or non-ST segment elevation MI in French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI), a nationwide French survey.


METHODS
Multiserotype ELISAs were performed to assess levels of IgG and IgA againstPorphyromonas gingivalis,Aggregatibacter actinomycetemcomitans,Prevotella intermediaandTannerella forsythia.


RESULTS
Adjusted HRs indicate the lack of association between IgG-anti-Po. gingivalislevels (0.96 (0.78 to 1.18)), IgA-anti-Po. gingivalislevels (1.13 (0.90 to 1.42)) and the risk of all-cause death or non-fatal MI at 1 year. Additionally, no significant association was found between the occurence of an event at 1 year and immunoglobulins levels against the others periodontopathogens.


CONCLUSIONS
The present data indicate that circulating levels of periodontopathogens antibodies are not associated with an increased risk of major adverse events in patients with a prior AMI. Studies dealing with bacterial and clinical data are needed to assess the role of oral health in comprehensive cardiac rehabilitation programmes.
Department of Periodontology, Rothschild Hospital (AP-HP); UFR of Odontology, University of Paris Diderot, Paris, France.|INSERM UMRS 011, Population-based Cohort Platform, Villejuif, France.
A
A
Boillot
Department of Periodontology, Rothschild Hospital (AP-HP); UFR of Odontology, University of Paris Diderot, Paris, France.|INSERM UMRS 1148, Laboratory for Vascular Translational Science, Paris, France.
H
H
Range
Department of Cardiology, AP-HP, Georges Pompidou European Hospital, Paris, France.|University of Paris-Descartes, Paris, France.
N
N
Danchin
Assistance Publique-Hôpitaux de Paris (APHP), St Antoine Hospital, URC-EST, Paris, France.
S
S
Kotti
INSERM UMRS 1148, Laboratory for Vascular Translational Science, Paris, France.
G
G
Cosler
INSERM UMRS 011, Population-based Cohort Platform, Villejuif, France.|Department of Nutrition, Ambroise Paré Hospital (AP-HP), University of Versailles Saint Quentin en Yvelines, Boulogne-Billancourt, France.
S
S
Czernichow
INSERM UMRS 1188, Diabète athérothrombose Thérapies Réunion Océan Indien, Sainte Clotilde, La Réunion, France.|La Réunion University, Sainte Clotilde, La Réunion, France.
O
O
Meilhac
Department of Cardiology, AP-HP, Georges Pompidou European Hospital, Paris, France.|University of Paris-Descartes, Paris, France.
E
E
Puymirat
Department of Cardiology, Dijon University Hospital, Dijon, France.
M
M
Zeller
Department of Cardiology, Clinique Pasteur, Toulouse, France.
D
D
Tchetche
Department of Periodontology, Rothschild Hospital (AP-HP); UFR of Odontology, University of Paris Diderot, Paris, France.|EA 2496, UFR of Odontology, University of Paris Descartes, Montrouge, France.
P
P
Bouchard
INSERM UMRS 1148, Laboratory for Vascular Translational Science, Paris, France.|Assistance Publique-Hôpitaux de Paris (APHP), St Antoine Hospital, URC-EST, Paris, France.|Department of Clinical Pharmacology, University of Pierre et Marie Curie, Paris, France.
T
T
Simon
Cardiovascular disease; Cohort studies; DENTAL HEALTH; Epidemiology of cardiovascular disease